Cartesian Therapeutics and WestGene Biopharma Form Strategic Licensing Agreement for Autoimmune Disease Platform

Cartesian Therapeutics, Inc. announced on Wednesday it has entered into a strategic licensing agreement with WestGene Biopharma. The agreement is designed to accelerate the development of Cartesian's in vivo CAR-T platform for the treatment of autoimmune diseases.

Under the terms of the agreement, WestGene Biopharma will gain a license to Cartesian's technology, enabling its use in research and development for specific immune-mediated disorders. This collaboration aims to enhance Cartesian Therapeutics' position in developing treatments for autoimmune conditions.

The licensing deal is expected to facilitate broader application of Cartesian's technology and provide additional resources for the platform's ongoing advancement. Both companies anticipate that the partnership will contribute to progress in the field.

Cartesian Therapeutics is focused on creating novel therapies for challenging diseases, while WestGene Biopharma specializes in drug development and clinical research.